Citations

Clear

1417 citation(s) found for "Simon, FM".

Computed tomography ‐derived extracellular volume fraction is associated with high‐grade recurrence in non‐muscle‐invasive bladder cancer treated with intravesical gemcitabine and docetaxel
Chakra, Mohamad Abou, Alsamarah, Issa, Hougen, Helen Y., Brown, James A. , Marchetti, Kathryn , Henning, Grant , Duquesne, Igor , Buhaş, Bogdan Adrian , O’Donnell, Michael A. , Hougen, Helen Y. , Duquesne, Igor , Buhas, Bogdan Adrian , O'Donnell, Michael A , Henning, Grant M , Chakra, Mohamad Abou , Zakharia, Yousef , Myers, Amanda A. , Mott, Sarah L.

Mayo Clinic

BJU International | May 28, 2026 | Volume: 138 | Issue: 2 | Pages: 306-314

10.1111/bju.70319 | PMID 42206900 Get It

Objectives To evaluate whether extracellular volume (ECV) fraction derived from contrast‐enhanced computed tomography (CT) is associated with recurrence risk in patients with treatment‐naïve high‐risk non‐muscle‐invasive bladder cancer (HR‐NMIBC) receiving intravesical gemcitabine/docetaxel (Gem/Doce) therapy. Patients and Methods This retrospective cohort study, conducted at a tertiary referral centre, included 103 patients with HR‐NMIBC treated with intravesical Gem/Doce between 2012 and 2024. All patients underwent pre‐resection contrast‐enhanced CT with an equilibrium phase (~3 min post‐injection). Tumour ECV fraction (%) was calculated using the formula: ECV = (ΔHUtumour/ΔHUaorta) × (1 − haematocrit) × 100, where Δ Hounsfield units (HU) represents the change in attenuation between non‐contrast and equilibrium phases. Regions of interest were manually placed in the tumour and abdominal aorta, and haematocrit values obtained within ±10 days were used. Associations between clinical variables, ECV, and recurrence were evaluated using Cox proportional hazards models, with discrimination assessed by Uno's C‐statistic. Results The median (interquartile range) follow‐up was 17 (10–25) months. High‐grade recurrence‐free survival (HG‐RFS) was 76% at 12 months and 69% at 24 months. CT‐derived ECV was the only variable significantly associated with HG‐RFS (hazard ratio 1.05, 95% confidence interval 1.03–1.08), demonstrating strong discrimination (C‐statistic, 0.81; P < 0.01). A 15% threshold offered the best sensitivity–specificity trade‐off (~70% each) for predicting HG‐RFS at 12 and 24 months. Patients with ECV ≤15% had markedly better HG‐RFS than those with ECV >15% at 24 months (88% vs 41%). Conclusions The CT‐derived ECV is a practical, first‐of‐its‐kind imaging biomarker associated with recurrence risk and useful for risk stratification in patients with HR‐NMIBC treated with intravesical Gem/Doce, a regimen increasingly used in the setting of global Bacillus Calmette‐Guérin shortages and intolerance. ECV can be rapidly quantified from routine contrast‐enhanced CT using standard picture archiving and communication system (PACS) tools, without additional imaging or proprietary software, making it a feasible metric for integration into risk‐adapted management pending large‐scale validation with extended follow‐up.
Impact of prior treatment setting on the efficacy of rucaparib vs physician’s choice in BRCA -mutated castration-resistant prostate cancer (mCRPC) in TRITON3.
Sridhar, Srikala S., Fizazi, Karim Olivier, Chowdhury, Simon, Ryan, Charles J. , Alonso-Gordoa, Teresa, Arranz, José Ángel, Birtle, Alison , Byard, Ian, Carrozza, Francesco , Giorgi, Ugo De, Duran, Ignacio, Goeminne, Jean-charles, Goldfischer, Evan R., Despain, Darrin, Craib, Marcia, Lindberg, Henriette , Sridhar, Srikala S , Fizazi, Karim , Bryce, Alan H. , Chowdhury, Simon, Alonso‐Gordoa, Teresa , Giorgi, Ugo De , Durán, Ignacio , Goeminne, Jean‐Charles, Goldfischer, Evan R., Grimm, Marc‐Oliver , Despain, Darrin , Craib, Marcia L.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 5054-5054

10.1200/jco.2026.44.16_suppl.5054 Get It

5054 Background: Rucaparib significantly improved radiographic progression-free survival (rPFS) versus physician’s choice of docetaxel or an androgen-receptor pathway inhibitor (ARPI) (abiraterone or enzalutamide) in men with BRCA mutations who were chemotherapy-naïve in the mCRPC setting and had received one prior ARPI in the phase 3 TRITON3 trial (NCT02975934). This post-hoc analysis evaluated whether the timing of prior ARPI therapy impacted the efficacy of rucaparib. Methods: Patients were randomized 2:1 to rucaparib (600 mg BID) or physician’s choice of docetaxel or ARPI, after progression on 1 prior second-generation ARPI in any setting. The primary endpoint was rPFS. Outcomes were analyzed according to whether patients received the prior ARPI in the metastatic castration sensitive (mCSPC) or castration resistant (mCRPC) setting. Data cutoff was August 25, 2022. Results: Of the 302 BRCA1/2 patients, 68 received prior ARPI in the mCSPC setting (42 rucaparib; 26 physician’s choice) and 234 in the mCRPC setting (159 rucaparib; 75 physician’s choice). Baseline characteristics were generally similar. Prior treatments in the mCSPC and mCRPC groups, respectively, included abiraterone (73.5% vs 53.0%), enzalutamide (29.4% vs 48.3%), and docetaxel (17.6% vs 24.8%). Median rPFS favored rucaparib over physician’s choice in both groups (mCSPC: 13.6 vs 8.2 months; HR 0.60 [95% CI, 0.32–1.15]; mCRPC: 11.2 vs 5.8 months; HR 0.43 [95% CI, 0.30–0.61]). Median OS was similar between treatments in both settings (mCSPC: 23.2 vs 21.7 months; HR 0.81 [95% CI, 0.47–1.41]; mCRPC: 23.2 vs 21.0 months; HR 0.91 [95% CI, 0.66–1.25]). Treatment-related adverse events occurred at comparable rates (89.6% vs 86.1%). Conclusions: Rucaparib demonstrated efficacy in patients with BRCA-mutated mCRPC, regardless of whether prior ARPI was administered in the mCSPC or mCRPC setting. Clinical trial information: NCT02975934 .
Post-hoc efficacy and biomarker analysis of elraglusib plus gemcitabine/nab-paclitaxel versus chemotherapy alone in metastatic pancreatic ductal adenocarcinoma.
Mahalingam, Devalingam, Shroff, Rachna, Carneiro, Benedito A., Ji, Yan, Cervantes, Andres, Sahai, Vaibhav , Ploquin, Anne , Hiret, Sandrine , Loconte, N, Percent, Ivor John, Lopez, Charles D., Pernot, Simon, Kavan, Petr, Mulcahy, Mary Frances, Giles, Francis J., Mazar, Andrew P. , Jaros, Mark, Bekaii-Saab, T., Sahai, Vaibhav , Mahalingam, Devalingam , Shroff, Rachna T. , Carneiro, Benedito A. , Coveler, Andrew L. , Cervantes, Andrés , LoConte, Noelle K. , Percent, Ivor , Lopez, Charles D. , Pernot, Simon , Kavan, Petr , Mulcahy, Mary F. , Carr, Ryan M , Bekaii-Saab, Tanios S

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 4213-4213

10.1200/jco.2026.44.16_suppl.4213 Get It

4213 Background: Elraglusib (9-ING-41), a glycogen synthase kinase-3β (GSK-3β) inhibitor, has multimodal antitumor activity. In the international, open-label, randomized phase 2 1801 Part 3B study, elraglusib plus gemcitabine/nab-paclitaxel (GnP) was evaluated in previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC), with patients randomized 2:1 to weekly elraglusib/GnP or GnP alone. Primary endpoints were median overall survival (mOS) and 1-year survival. The GnP control arm demonstrated shorter mOS than contemporary randomized trials (7.2 months vs 9.2 months in NAPOLI-3 and 9.7 months in PASS-01), driven by higher early mortality (0–2 months: 23.1% vs 10.1% in NAPOLI-3). Given balanced randomization, similar early mortality was inferred in the elraglusib/GnP arm, prompting post-hoc analyses to contextualize efficacy and identify factors associated with early death. Methods: Efficacy and safety were summarized descriptively. Time-to-event endpoints were analyzed using Kaplan–Meier estimates, log-rank testing, and Cox proportional hazards models. Response rates were compared using the Cochran–Mantel–Haenszel test. Post-hoc subgroup, sensitivity, and machine-learning–based multivariate analyses explored clinical, demographic, and biomarker correlates of survival and early mortality. Results: In the full randomized population (elraglusib/GnP n=155; GnP n=78), elraglusib/GnP improved mOS by 2.9 months versus GnP (10.1 vs 7.2 months; HR 0.62; 95% CI 0.46–0.84; p=0.01), with 1-year survival rates of 44.1% versus 22.3%. Among patients receiving ≥1 full treatment cycle, mOS was 12.5 months with elraglusib/GnP and 8.5 months with GnP, comparable to contemporary registrational trials. Across multiple post-hoc sensitivity analyses—including evaluable patients, those matched to NAPOLI-3 baseline tumor burden, patients treated in the EU (early mortality 4%), and those achieving ≥20% CA19-9 decline within the first 1–2 cycles—elraglusib/GnP consistently demonstrated a ≥4-month OS advantage. Early death was associated with low baseline albumin (<3 g/dL), high CA19-9 (>800 U/mL), high tumor burden, and KRAS, TP53, and CDKN2A co-mutations. Conclusions: The elevated early mortality in the GnP control arm reflects enrollment of a heterogeneous, real-world mPDAC population with less restrictive eligibility than recent registrational trials. Post-hoc analyses identify key clinical and molecular drivers of early death and confirm a consistent survival benefit with elraglusib/GnP. These hypothesis-generating findings directly inform eligibility criteria, stratification, and endpoint assumptions for the planned phase 3 trial. Clinical trial information: NCT03678883 .
Examining burnout, work–life balance, relocation and financial stress among UK resident doctors and medical students
Rehman, Umar , Chin, Kai Jian , Kungwengwe, Garikai , Perwaiz, Ibrar, Aktar, Lahreb, Choudhury, Rozina Yasmin, Jaffee, Ally, Pereira, Mariam, Arab, Sammy, Chhatwal, Karanjot , Filson, Simon, Cavale, Naveen , Hafner, Marco , Hankir, Ahmed, Brennan, Peter, Lechner, Matt, Group, WARM Study Collaborators, Arab, Sammy , Arab, Sammy , Rehman, Umar , Perwaiz, Ibrar , Sarwar, Mohammad Sohaib , Filson, Simon A. , Hankir, Ahmed Khaldoon , Lechner, Matt

Mayo Clinic

The British Journal of Psychiatry | May 26, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-8

10.1192/bjp.2026.10666 | PMID 42187538 Get It

Background Burnout arises from prolonged, unresolved work-related stress and adversely affects professional performance and overall well-being. Resident doctors and medical students are particularly vulnerable because of the demands of balancing clinical, academic and related responsibilities. Aims This study aimed to assess self-reported burnout and related stressors among UK resident doctors and medical students, and estimate the economic impact of burnout-related absenteeism among resident doctors. Method Self-report questionnaires assessing burnout and related stressors were distributed to UK resident doctors and medical students. A total of 2793 responses were received: 1439 (51.5%) from resident doctors and 1354 (48.5%) from medical students. Economic losses from absenteeism were calculated with a human capital approach. Results Burnout was reported by 70% ( n = 1008) of resident doctors and 65.7% ( n = 889) of medical students. Notably, 56.8% ( n = 573) and 79.3% ( n = 705) of resident doctors and medical students affected by burnout, respectively, were unaware of available support services. Relocation stress (85.1% of residents and 62.6% of students), financial stress (53.9% of residents and 57.8% of students) and poor work–life balance (32.1% of residents and 20.7% of students) were commonly reported. The annual economic burden of absenteeism related to burnout among resident doctors was estimated to reach £251.5 million. Conclusions Burnout among UK resident doctors and medical students may reflect a combination of underlying factors, including financial strain, relocation stress and difficulties with work–life balance. These findings underscore the need for targeted interventions that support well-being and address financial and relocation challenges, which may, in turn, help prevent burnout and improve retention within the medical workforce. Reducing burnout and associated stressors may also help lessen its economic impact, allowing resources to be redirected towards patient care.
Implementation of a Bedside Percutaneous Dilatational Tracheostomy Program in a Pulmonary and Critical Care Fellowship: Enhancing Patient Safety with a Checklist
Fernandes, Mateus , Schwartz, Jacob, GREENSTEIN, ZACK, Shayani, Kevin, PATEL, SONICA, Eldeiry, D, Zimnoch, Mary, Lakticova, Viera, Oks, Margarita, Meredith, Simon , Meredith, Simon , Shayani, Kevin E. , Laktičová, Viera, Singh, Anup K. , Oks, Margarita

Mayo Clinic

Journal of Intensive Care Medicine | May 23, 2026 | Volume: 41 | Issue: 8 | Pages: 794-802

10.1177/08850666261446923 | PMID 42175802 Get It

Background Bedside percutaneous dilatational tracheostomy is a commonly performed procedure in the Intensive Care Unit with a steep learning curve. Checklists and standardized protocols have been established as essential tools for mitigating medical error and enhancing patient safety during critical care procedures. Research Question To assess the feasibility and safety profile of a percutaneous tracheostomy protocol, performed by pulmonary and critical care fellows, which integrates a multi-component checklist, tracheal ultrasound and a unique dual-visualization technique for endotracheal tube management. Study Design and Methods We conducted a retrospective review of all patients (n = 49) who underwent bedside percutaneous tracheostomy using a standardized protocol between November 1, 2022, and October 31, 2024. Key components of the protocol included rigorous pre-procedure assessment with standard tracheal ultrasound stations, a mandatory checklist, and endotracheal tube retraction under dual video laryngoscopy and bronchoscopy. Outcomes analyzed included major bleeding, site infection, and airway complications. Results A total of 49 percutaneous tracheostomy procedures were successfully performed over the 24-month period. No major bleeding episodes or pressure ulcers were identified. There was a single complication involving loss of airway due to endotracheal tube balloon rupture. Critically, the patient was rapidly re-intubated without any hypoxemia or hemodynamic instability, which may be attributed to the immediate availability and use of the dual-visualization safeguard. Interpretation The implementation of this protocolized, checklist-driven approach to bedside percutaneous tracheostomy is feasible and safe within the framework of a pulmonary and critical care fellowship training model. The use of a novel dual-visualization technique (video laryngoscopy and bronchoscopy) during endotracheal tube retraction serves as a robust fail-safe, which may enhance patient safety during airway-compromised events.
Early suicidal ideation change and suicidality-associated emergency department utilization after ketamine or esketamine treatment in treatment-resistant depression
Patarroyo-Rodríguez, Liliana , Pazdernik, Vanessa K., Voort, Jennifer L. Vande, Kung, Simon , Singh, Balwinder , Singh, Balwinder , Voort, Jennifer L. Vande

Mayo Clinic

Therapeutic Advances in Psychopharmacology | May 23, 2026 | Volume: 16 | Issue: No issue available | Pages: No page available

10.1177/20451253261450747 | PMID 42186575 Get It

Background: Ketamine and esketamine ((es)ketamine) rapidly reduce depressive symptoms and suicidal ideation (SI) in treatment-resistant depression (TRD), but whether early SI improvement during the acute phase of the treatment predicts reduced suicide-associated emergency department (SAED) visits over the longer term remains unclear. Objectives: To examine whether early improvements in SI, measured using item 12 of the Quick Inventory of Depressive Symptomatology – Self Reported (QIDS-SR), following (es)ketamine treatment are associated with SAED visits over 6 months Design: Retrospective cohort study. Methods: Individuals with TRD who had available data on SI measured using the QIDS-SR during the acute phase, as well as data on SAED visits over 6 months, were included. Participants were classified based on changes in SI as resolved, partially improved, or unchanged/worsened using the QIDS-SR item 12 during acute treatment (up to six intravenous (IV) or eight intranasal (IN) treatments) and were followed for SAED visits. Results: Among 96 patients with SI data, 73 (76%) had baseline SI. Following acute-phase treatment, 36 (49%) achieved SI resolution, 14 (19%) partially improved, and 23 (32%) were unchanged/worsened. During the 6-month follow-up, 8 (11%) had post-acute SAED visits. While not statistically significant, patients with resolved SI had lower odds of post-acute ED visits (OR = 0.16, p = 0.12). Kaplan–Meier estimates of SAED visit-free survival across three SI change groups trended toward significance ( p = 0.066), suggesting lower cumulative healthcare (ED) utilization in more favorable change groups. Secondary analysis among 57 patients who received IV ketamine and had baseline SI showed that, after two infusions, 33 (47.2%) demonstrated a reduction in SI. Early SI improvement (⩾50% reduction in SI) was associated with a lower likelihood of any post-treatment SAED visit at 6 months after adjusting for pre-treatment SAED (OR = 0.17, 95% CI: 0.02–0.98, p = 0.047), corresponding to numbers needed to treat of 4.3. Conclusion: Early SI changes may have prognostic implications, though larger studies are needed to confirm clinical significance.
Abstract 4003: Path-IO: A deep learning pathomics framework for personalized immunotherapy selection and outcome prediction in metastatic non-small cell lung cancer
Bandyopadhyay, Rukhmini, Hong, Linghzi, Aldea, M, Li, Shenduo , Saad, Maliazurina B., Zhang, Jiexin, Showkatian, Eman , Arrechedera, Claudio A. , Han, Xiaoyu , Kitsel, Yuliya , Ismail, Sherif, Aminu, Muhammad , Zhu, Bo, Wu, Carol C., Carter, B., Chang, Joe Y, Liao, Zhongxing, Ghigna, Maria R., Tran, Hai T., Le, Xiuning, Cascone, Tina , Zhang, Bingnan, Araujo, Haniel A., Altan, Mehmet, Jaffray, David, Gibbons, Don L., Vaporciyan, Ara, Lee, J Jack, Kalhor, Neda , Haymaker, C, Wistuba, Ignacio, Heymach, John V., Lou, Yanyan, Vokes, N. , Soto, Luisa M. Solis, Zhang, Jianjun, Wu, Jia, Aldea, Mihaela , Zullo, Lodovica , Rojas, Frank R. , Saad, Maliazurina B. , Marin, Maricel C., Waqas, Muhammad , Ismail, Sohair , Zhu, Bo , Wu, Carol C. , Liao, Zhongxing , Ghigna, Maria‐Rosa , Soldato, Davide , Tran, Hai T., Le, Xiuning , Zhang, Bingnan , Araújo, Haniel Alves , Altan, Mehmet , Heeke, Simon , Gibbons, Don L , Vaporciyan, Ara A. , Lee, J Jack, Wistuba, Ignacio I. , Heymach, John V. , Soto, Luisa M. Solis , Zhang, Jianjun , Wu, Jia

Mayo Clinic

Cancer Research | May 15, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 4003-4003

10.1158/1538-7445.am2026-4003 Get It

Abstract Background: Immune checkpoint inhibitors (ICIs) have improved survival in non-small-cell lung cancer (NSCLC), yet only a subset of patients benefits, and biomarkers like PD-L1 remain limited. Here, we introduce a deep learning-based pathomics framework that utilizes routine H&E-stained slides to predict therapeutic response and survival outcomes in ICI-treated metastatic NSCLC. Methods: The study included 797 ICI-treated NSCLC patients from MD Anderson, with external validation in 280 patients from Mayo Clinic, Gustave Roussy, and the Phase III ICI-naïve LUSC Lung-MAP S1400I trial receiving nivolumab with or without ipilimumab. Path-IO (Pathology-Driven Immunotherapy Optimization) comprised of four major steps: (1) pathologist-verified tissue classifier segmented WSIs into eight compartments—Background, Bronchi, Immune, Lung, Necrosis, Stroma, Tumor, and Vessel—and was validated on TCGA and CPTAC dataset; (2) a survival prediction module generating patient-level risk scores in the MD Anderson cohort and validated across external datasets; (3) integration of Path-IO risk scores with radiomics and clinical features to improve prognostic accuracy; and (4) biological interpretability analyses correlating Path-IO risk immune contexture from multiplex immunofluorescence and transcriptomic signatures from NanoString profiling. Results: Path-IO effectively stratified patients into high and low-risk groups with significant survival differences. In the MD Anderson cohort, it achieved HR = 2.11 (p &lt; 0.001) and HR = 2.51 (p &lt; 0.001) for OS in the discovery and validation sets, and HR = 2.34 (p &lt; 0.001) and HR = 1.87 (p &lt; 0.001) for PFS, respectively. In the multicenter Phase III Lung-MAP S1400I trial, Path-IO achieved HR = 1.78 (p = 0.016) for OS and HR = 2.76 (p = 0.006) for PFS. In external validation, it predicted outcomes in the Gustave Roussy (OS = 1.97, p = 0.003; PFS = 1.51, p = 0.046) and Mayo Clinic (OS = 2.46, p = 0.007; PFS = 2.45, p = 0.027) cohorts. Path-IO outperformed PD-L1 and remained an independent predictor in multivariate analysis (p &lt; 0.001). It enabled data-driven frontline selection between anti-PD-1 monotherapy and chemo-immunotherapy, offering guidance toward more personalized treatment decisions. Integration with radiomics and clinical features further improved predictive accuracy (OS 0.63→0.75; PFS C-index 0.58→0.70), while high Path-IO risk scores correlated with immune-cold phenotypes identified by multiplex immunofluorescence and NanoString transcriptomics. Conclusions: Path-IO demonstrates that deep learning models rooted in histopathologic architecture can generate interpretable and biologically informed survival predictions in NSCLC treated with ICIs. By integrating pathology, radiology, and clinical data, Path-IO provides complementary predictive value beyond established biomarkers such as PD-L1. Citation Format: Rukhmini Bandyopadhyay, Linghzi Hong, Mihaela Aldea, Shenduo Li, Lodovica Zullo, Frank R. Rojas, Maliazurina B. Saad, Maricel C. Marin, Muhammad Waqas, Jiexin Zhang, Eman Showkatian, Claudio A. Arrechedera, Xiaoyu Han, Yuliya Kitsel, Sherif Ismail, Muhammad Aminu, Bo Zhu, Carol C. Wu, Brett W. Carter, Joe Y Chang, Zhongxing Liao, Maria R. Ghigna, Davide Soldato, Hai T. Tran, Xiuning Le, Tina Cascone, Bingnan Zhang, Haniel A. Araujo, Mehmet Altan, Simon Heeke, David Jaffray, Don L. Gibbons, Ara Vaporciyan, J Jack Lee, Neda Kalhor, Cara Haymaker, Ignacio Wistuba, John V. Heymach, Yanyan Lou, Natalie Vokes, Luisa M. Solis Soto, Jianjun Zhang, Jia Wu. Path-IO: A deep learning pathomics framework for personalized immunotherapy selection and outcome prediction in metastatic non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 4003.
Functional Outcomes in Bipolar Disorder: Cross-Cohort Analyses from the Global Bipolar Cohort
Yocum, *Anastasia K., Fullerton, *Janice M., Ashton, Melanie M., Overs, Browyn J., Diaz‐Byrd, Claudia , Albarracín-García, Lucía , Alda, Martin, Alexander, Nina , Altimus, Cara M. , Altınbaş, Kürşat, Andreassen, Ole A., Aubin, V. , Baca-García, Enrique, Baune, Bernhard T., Belzeaux, Raoul , Benavente-López, Sergio, Bengesser, Susanne A., Berk, Michael, Biernacka, Joanna, Blumberg, Hilary P., Burdick, Katherine E., Carpiniello, Bernardo, Chang, Chiao-Erh , Chen, Wen Yin, Clark, Scott R., Cleare, Anthony J., Contu, Martina , Dafnas, Konstantinos , Dannlowski, Udo, Dikeos, Dimitris, Dodd, Seetal, Dols, Annemieke, Dubertret, C, Etain, Bruno, Eyler, Lisa T., Fatjó‐Vilas, Mar , Ferentinos, Panagiotis, Ferguson, B. , Fernández, Ana L., Flinkenflügel, Kira, Forester, Brent P. , Fries, Gabriel R., Frye, Mark A., Fuentes-Claramonte, Paola, Gard, Sébastien, Gergel, Tania, Godin, O, Green, MJ, Haffen, E, Hahn, Tim, Havard, Alys, Jamalabadi, Hamidreza, Jansen, Andreas, Jones, I, Jones, Lisa A., Kelsoe, John R., Kircher, Tilo, Klaus, Federica, Kulkarni, Jayashri , Kupka, Ralph W., Leboyer, M, Lenger, Melanie , McElroy, Susan L., Machado-Vieira, Rodrigo, Manchia, Mirko, Martin, Nicolas G., Mata-Iturralde, Laura, Meinert, Susanne, Mitchell, Philip B., Mitra, Romita, Mohebbi, Mohammadreza , Mwangi, Benson, Nenadić, Igor, Nierenberg, Andrew A., Nunes, Abraham, Olié, E, O'Donovan, Clair, Orhan, Melis M., Passerieux, Christine, Perich, Tania, Peters, Amy T. , Petite, Joanne, Pham, Dániel , Pinna, M A, Platzer, Martina, Polosan, Mircea , Pomarol-Clotet, Edith, Porta-Casteràs, Daniel, Potter, Julia R., Quidé, Yann, Regeer, Eline J. , Rheenen, Tamsyn E. Van, Roberts, Gloria, Rodríguez-Cano, Elena, Rossell, Susan L., Sajatovic, Martha, Salvador, Raymond, Samalin, Ludovic, Sánchez-Alonso, Sergio, Sarró, Salvador , Schubert, Klaus O., Schwan, R, Scott, Katie , Shanahan, Megan, Soares, Jair C., Solé, Brisa, Stein, Dan J., Stein, Frederike, Strakowski, Stephen M., Straube, Benjamin, Strawbridge, Rebecca, Sullivan, Patrick F., Teutenberg, Lea, Thiel, Katharina , Thomas-Odenthal, Florian, Toma, Claudio, Usemann, Paula L., Vieta, Eduard, Vilella, Elisabet, Viswanath, Biju, Williams, Lana J., Wu, Mon-Ju, Yatham, Lakshmi N., Young, Allan H., McInnis, Melvin G., Almeida, Jorge, Bora, Emre, Cannon, Dara M., Chang, Yun-Hsuan, Chaumette, Boris, Chen, Jun, Ching, Christopher, Escamilla, Michael , Forstner, Andreas J., Goghari, Vina M. , He, Qin, Huang, Hailiang, Juruena, Mario F.; id_orcid 0000-0001-8558-3396, Kasyanov, Evgeny D., Koenig, B., Kovács, Zoltán , Kulkarni, Alok, Lee, Heon-Jeong, Lee, Jimmy, Liao, Duanping , LICHT, RASMUS W., Melle, Ingrid, Nicolini, Humberto, Okawa-Belizario, Gabriel, Prieto, Miguel L. , Raventós, Henriette , Ardestani, Seyed M. Samimi, Saunders, Erika F., Savitz, Jonathan, Schulze, Thomas G., Serretti, Alessandro, Simhandl, Christian , Straszek, Sune, SOUSA, RAFAEL TEIXEIRA DE , Thompson, Paul M., Tondo, Leonardo, Tourjman, S. Valérie, Zandi, Peter, Quidé, Yann , Overs, Bronwyn J. , Quidé, Yann , Sarró, Salvador , Yocum, Anastasia K. , Fullerton, Janice M. , Ashton, Melanie M. , Alda, Martin , Alonso-Lana, Sílvia , Altınbaş, Kürşat , Andreassen, Ole A , Antoniou, Anastasia , Baca‐García, Enrique , Baune, Bernhard T., López, Sergio Benavente , Berk, Michael , Beunders, Alexandra J.M. , Blumberg, Hilary P. , Brosch, Katharina , Burdick, Katherine E. , Callahan, Tiffany J , Cano, Marta , Cardoner, Narcı́s , Carpiniello, Bernardo , Chen, I‐Ming , Clark, Scott , Cleare, Anthony J. , Dalkner, Nina , Dannlowski, Udo , Dikeos, Dimitris, Dodd, Seetal , Dols, Annemiek , Dubertret, Caroline , Étain, Bruno , Eyler, Lisa T. , Fellendorf, Frederike T. , Flinkenflügel, Kira , Di Florio, Arianna , Fries, Gabriel R. , Frye, Mark A. , Fuentes‐Claramonte, Paola , Gergel, Tania , Godin, Ophélia , Gordon‐Smith, Katherine , Haffen, Emmanuel , Hahn, Tim , Hartmann, Simon , Havard, Alys , Hickie, Ian Bernard , Jamalabadi, Hamidreza , Jansen, Andreas , Kelsoe, John R , Kircher, Tilo , Klaus, Federica , Kuo, Po‐Hsiu , Kupka, Ralph , Lagerberg, Trine Vik , Leboyer, Marion , Lind, Penelope A. , McElroy, Susan L. , Machado‐Vieira, Rodrigo , Manchia, Mirko , Martínez‐Arán, Anabel , Medland, Sarah E. , Meinert, Susanne L. , Miklowitz, David J. , Millett, Caitlin E. , Mitchell, Philip B , Muntané, Gerard , Mwangi, Benson , Nenadić, Igor , Nierenberg, Andrew A. , Nurnberger, John I , Olié, Émilie , Orhan, Melis , Paribello, Pasquale , Passerieux, Christine , Perich, Tania , Pisanu, Claudia , Pomarol‐Clotet, Edith , Casteràs, Daniel Porta , Potter, Julia R, Reininghaus, Eva , Van Rheenen, Tamsyn , Ringin, Elysha , Ritter, Philipp , Roberts, Gloria, Rodríguez‐Cano, Elena , Rossell, Susan Lee , Sajatovic, Martha , Samalin, Ludovic , Scaini, Giselli , Schofield, Peter R. , Schouws, Sigfried N. T. M. , Schubert, Klaus Oliver , Schwan, Raymund , Shanahan, Megan, Siskind, Dan , Soares, Jair C. , Squassina, Alessio , Stein, Dan J. , Stein, Frederike , Strakowski, Stephen M. , Straube, Benjamin , Strawbridge, Rebecca , Stuart, Amanda L. , Teutenberg, Lea , Thomas‐Odenthal, Florian , Toma, Claudio , Torres, Ivan J. , Tsapekos, Dimosthenis , Ueland, Torill , Usemann, Paula L , Vieta, Eduard , Vilella, Elisabet , Viswanath, Biju , Winter, Alexandra , Wootton, Olivia , Wrobel, Anna L , Yatham, Lakshmi N. , Young, Allan H. , McInnis, Melvin G. , Bora, Emre , Cannon, Dara M. , Chaumette, Boris , Forstner, Andreas J. , Grigoroiu‐Serbânescu, Maria , He, Qin , Juruena, Mário F. , Kasyanov, Evgeny Dmitrievich , Koenig, Barbara, Lafer, Beny , Vernal, Ditte Lammers , Lee, Heon‐Jeong , McMahon, Francis J. , McQuillin, Andrew , Melle, Ingrid , Najand, Babak , Nicolini, Humberto , Belizário, Gabriel Okawa , Redlich, Ronny , Ardestani, Seyed Mehdi Samimi , Saunders, Erika F.H. , Savitz, Jonathan B. , Schulze, Thomas , Serretti, Alessandro , Σκώκου, Μαρία , Straszek, Sune Puggaard Vogt , Sousa, Rafael Teixeira de, Thompson, Paul M. , Tondo, Leonardo , Xiong, Ashley

Mayo Clinic

No container title available | May 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9390347/v1 Get It

Abstract Background The Global Bipolar Cohort (GBC) was established to identify existing bipolar disorder (BD) cohorts worldwide and foster collaborations focused on descriptive and analytic outcomes relevant to BD. A distributed analytic framework has been implemented to engage multiple sites without the need for central data pooling. This report describes the GBC endeavor and global functional impairment patterns. Cross-cohort comparisons of functional correlates are limited by heterogeneous measures and data-sharing constraints. Large, culturally diverse comparisons are needed to distinguish broadly reproducible correlates from cohort-specific effects. Participating sites completed a 28-item descriptive survey covering diagnostic methods, cognition, genetics, treatment, functioning, and follow-up strategies. We implemented a harmonized local logistic regression model of dichotomized functional outcome and shared summary statistics only. Results We identified 69 cohorts across five continents. Thirty-seven cohorts contributed functional outcome analyses from 17,130 participants. Outcome measures included clinician-rated disability scales and social indicators such as employment and marital status. The proportion classified with poor functioning ranged from 16% to 77% (mean 50%). In 32 of 37 cohorts, the overall regression model significantly explained variance in functioning. Current depressive symptoms were the most robust and reproducible correlate of poor functional outcome: they were assessed in 29 cohorts, significant in 22 (75.8%), ranked among the top three correlates in 22, and were the top-ranked correlates in 19. Associations between depressive burden and poor functioning were observed across clinician-rated disability scales and work or social indicators, and across geographically diverse cohorts. Comorbid substance use disorder and medication-related variables were associated with poorer functioning in subsets of cohorts, whereas sex, ancestry, bipolar subtype, psychosis history, and premorbid IQ showed weak or inconsistent associations. Cognitive measures, available in a minority of regression models, showed modest and non-uniform effects. Conclusions Across heterogeneous international cohorts, current depressive symptom burden emerged as the most consistent correlate of poor functioning in bipolar disorder. These findings replicate earlier multisite work at a larger scale, show that protocol-based distributed analyses can identify reproducible clinical signals without sharing individual-level data, and support prioritizing detection and treatment of depressive symptoms when aiming to improve real-world functioning. Future work should expand longitudinal harmonization and representation of under-studied populations.
ABSTRACT NUMBER: ESOC2026A1166 PERSISTENCE WITH BOTULINUM TOXIN A AND FACTORS ASSOCIATED WITH DISCONTINUATION IN PATIENTS WITH STROKE: A RETROSPECTIVE COHORT STUDY
Wainberg, Michael, Page, Simon, Zhang, Jinming , Rangarajan, Nivedita , Kumar, Sandeep, Bouchard, Jonathan, Mann, Amandeep, Beneteau, Mathieu, Schultz, Billie, Page, Simon , Mann, Amandeep, Beneteau, Mathieu , Schultz, Billie A.

Mayo Clinic

European Stroke Journal | May 6, 2026 | Volume: 11 | Issue: Supplement_1 | Pages: i333-i334

10.1093/esj/aakag023.578 Get It

Abstract Background and aims BotulinumtoxinA (BoNT-A) is a guideline-recommended treatment for spasticity following stroke. We evaluated BoNT-A treatment persistence drivers of discontinuation and predictors of non-persistence in patients with stroke. Methods Eligible adults had received ≥1 treatment cycle with BoNT-A at the Mayo Clinic (January 2010–June 2023) and had an International Classification of Diseases (ICD9/10) code for stroke. Patients with ICD9/10 codes for migraine, cerebral palsy, cervical dystonia, or bladder dysfunction were excluded. Index date (baseline) was the date of first BoNT-A treatment; follow-up was 2 years post-index. Patients were persistent if all treatment intervals post-index were ≤the 80th percentile of all patients. Reasons for discontinuation were identified by AI natural language processing analysis of physicians’ free-text notes. Baseline characteristics associated with non-persistence were identified using step-wise logistic regression analyses. Results Overall, 407 patients were included. The 80th percentile of the BoNT-A treatment interval was 154 days; 5.7% of patients were persistent. Mean (95%CI) number of BoNT-A treatments over the 2-year follow-up was 2.43 (2.24–2.63) cycles. Comorbidity burden was high (Table 1). The most common reasons for BoNT-A discontinuation were patient- and physician-reported lack of treatment effectiveness (Table 2). Older age, Hispanic/Latino/unknown/undisclosed ethnicity, presence of comorbidities, and use of medications of interest at baseline (skeletal muscle relaxants, antidepressants, anticonvulsants, opiates, sedatives/hypnotics, NSAIDs) were significantly associated with non-persistence (Table 3). Conclusions Over 2 years, BoNT-A treatment persistence was low. Lack of treatment effectiveness was the most common reason for discontinuation. Addressing drivers of non-persistence may help improve BoNT-A treatment outcomes. Conflict of interest Funding: Ipsen. Disclosure of Conflicts of Interest: Michael Wainberg: has received consulting fees from Ipsen. Billie Schultz: has received consulting fees from Ipsen. Jinming Zhang, Simon Page, Jonathan Bouchard, Amandeep Mann, Mathieu Beneteau are employees of Ipsen. Table 1 - belongs to Conclusions Table 2 - belongs to Conclusions Table 3 - belongs to Conclusions
Multi‐Frequency Electrocochleography Results in Fewer Drop Alarms During Cochlear Implant Insertion
Espahbodi, Mana , Syed, Ali, Tu, Alex, Seidman, Michael D. , Danner, Christopher J., Allen, Kyle P., Bartels, Loren J., Ahsan, Syed F. , Voelker, Courtney C. J. , Deep, Nicholas L. , Chiffer, Rebecca C., Elrakhawy, Mohamed, Miller, Matthew W., Lin, Harrison W., Djalilian, Hamid R. , Angeli, Simon I., Kim, H J, Widick, Mark H., Stidham, Katrina R. , Patel, Neil S. , Koka, Kanthaiah , Hunter, Jacob B , Djalilian, Hamid R , Stidham, Katrina R , Gurgel, Richard Klaus , Doerfer, Karl W , Harris, Michael S , Danner, Christopher, Bartels, Loren Jay, Hunter, Jacob B. , Michaelides, Elias M. , Miller, Matthew W, Vivas, Esther , Angeli, Simón I., Hoa, Michael , Harris, Michael S.

Mayo Clinic

The Laryngoscope | May 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/lary.70592 | PMID 42084107 Get It

ABSTRACT Objective To evaluate intracochlear electrocochleography (ECochG) amplitude parameters during cochlear implantation (CI) using a novel multi‐frequency ECochG algorithm. Methods A multi‐institutional, prospective cohort study was performed at 18 high‐volume CI centers. The inclusion criteria were adults with sensorineural hearing loss and audiometric thresholds of ≤ 90 dB hearing level at 500 Hz undergoing CI with Advanced Bionics (Valencia, CA) Ultra 3D devices between 2024 and 2025. ECochG recordings were performed with simultaneous multi‐frequency stimulation of four frequencies between 125 and 4000 Hz during cochlear implant insertion. Concurrent multi‐frequency recording allowed extraction of amplitude and phase of each frequency individually. Post hoc analysis was performed to determine the difference in the number of drop alarms between single‐ and multi‐frequency ECochG. An ECochG amplitude drop of 6 dB was defined as a drop alarm. Insertion track patterns were compared between single‐ and multi‐frequency ECochG. Results One hundred ninety‐five ears were included. Mean number of drop alarms for the single‐frequency algorithm was 1.72 (95% CI: 1.52, 1.92; median 1) compared to 0.42 (95% CI: 0.31, 0.53; median 0) for multi‐frequency; p < 0.001. The number of Type C patterns (rise in amplitude during insertion followed by a drop) decreased with the multi‐frequency ECochG algorithm compared to the single‐frequency ECochG algorithm. The number of Type D patterns (no‐response) decreased, indicating that multi‐frequency ECochG generated more responses across the cochlea than single‐frequency ECochG. Conclusions A novel multi‐frequency ECochG algorithm during CI is associated with fewer drop alarms and altered insertion track patterns, which may provide a more accurate assessment of the cochlear microenvironment. Level of Evidence 3.